31 results
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 May 24
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7:15am
as of March 31, 2024, will enable it to fund its operating plan into 2026.
R&D Expense: Research and development expenses for the first quarter of 2024 were …
(in thousands, except per share amounts)
Three Months Ended
March 31,
Operating expenses:
Research and development
General and administrative
Total
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
and business development, including external research and development, mergers & acquisitions, Amgen ventures and alliance management. Prior to that Mr …
Paul L. Berns
Executive Chairman
Robert Lenz, M.D., Ph.D.
Head of Research and Development
Jason Duncan
Chief Legal Officer
Daljit (Bill) Singh Aurora
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
expectations with regard to the results of our clinical studies, preclinical studies and research and development programs, including the timing … ;
the timing of commencement of future preclinical studies and clinical trials and research and development programs;
our ability to acquire
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7:08am
operating plan into 2026.
R&D Expense: Research and development expenses for the fourth quarter of 2023 were $38.9 million, as compared to $23.5 million … for the same period in 2022. Research and development expenses for the full year ended December 31, 2023 were $142.7 million, compared to $91.7
10-Q
a2lnc3qoh
1 Nov 23
Quarterly report
4:05pm
8-K
EX-99.1
7sn9yvghej
1 Nov 23
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:01pm
424B4
n80u3v61qhc l807z6
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
xntcsxru1n592vojrxt
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-1.1
irsqetm2wt3
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-10.14
afdioq yvx1v8t8v
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.4
6f080tok
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.3
7fibfo 40qkz4d4
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.5
lbv 1s5yeabq
25 Aug 23
IPO registration
5:03pm
S-1
aphbpx6
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.2
uoz7r5somx drcac
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.10
285f 2lpjfz
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.18
8xhes9a23
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.2
m0dpg96rrvq64nb0
25 Aug 23
IPO registration
5:03pm
DRS/A
EX-10.19
szzypf0qf7kza
9 Aug 23
Draft registration statement (amended)
12:00am